TY - JOUR
T1 - Investigating crystallization tendency, miscibility, and molecular interactions of drug–polymer systems for the development of amorphous solid dispersions
AU - Meng, Fan
AU - Paul, Sagar Kumar
AU - Borde, Shambhavi
AU - Chauhan, Harsh
N1 - Funding Information:
The author wishes to acknowledge Creighton University, Omaha, for funding and the use of instruments in completing this project.
Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Crystallization tendencies, thermal analysis [i.e. glass transition temperature (T g)], crystallinity, and melting point depression, along with theoretical calculations such as solubility parameter, of five different drugs [i.e. curcumin (CUR), indomethacin (IND), flutamide (FLU), dipyridamole (DIP), and griseofulvin (GRI)] in the absence and presence of four different polymers in various drug–polymer ratios were determined and analyzed. Physical states of the drug in the solid dispersions (SDs) and their stability were characterized by X-ray diffraction and modulated differential scanning calorimetry. Infrared (IR) and Raman were used in selected systems (i.e. CUR, DIP, and GRI systems) to explore the role of drug–polymer interactions in the amorphization of SDs. The crystallization tendencies of pure drugs were categorized as low (CUR, IND), moderate (FLU), and high (DIP, GRI). In the presence of selected polymers, the crystallization tendency of the drugs changed, though a high polymer concentration was required for high crystallization-tendency drugs [i.e. DIP and GRI (>50% w/w)]. Polymers showing a greater effect on the crystallization tendency of drugs were found to have higher drug–polymer miscibility and stronger molecular interactions. Drug–polymer systems selected from the investigation of physical mixtures formed stable amorphous solid dispersions (ASD). Furthermore, the rank order of the crystallization tendency of drug–polymer systems correlated well with those on miscibility and molecular interactions. Those rank orders also correlated well with the stability of prepared/reported SDs. Hence, the developed approach has significant potential to be a rational screening method for the development of amorphous SDs.
AB - Crystallization tendencies, thermal analysis [i.e. glass transition temperature (T g)], crystallinity, and melting point depression, along with theoretical calculations such as solubility parameter, of five different drugs [i.e. curcumin (CUR), indomethacin (IND), flutamide (FLU), dipyridamole (DIP), and griseofulvin (GRI)] in the absence and presence of four different polymers in various drug–polymer ratios were determined and analyzed. Physical states of the drug in the solid dispersions (SDs) and their stability were characterized by X-ray diffraction and modulated differential scanning calorimetry. Infrared (IR) and Raman were used in selected systems (i.e. CUR, DIP, and GRI systems) to explore the role of drug–polymer interactions in the amorphization of SDs. The crystallization tendencies of pure drugs were categorized as low (CUR, IND), moderate (FLU), and high (DIP, GRI). In the presence of selected polymers, the crystallization tendency of the drugs changed, though a high polymer concentration was required for high crystallization-tendency drugs [i.e. DIP and GRI (>50% w/w)]. Polymers showing a greater effect on the crystallization tendency of drugs were found to have higher drug–polymer miscibility and stronger molecular interactions. Drug–polymer systems selected from the investigation of physical mixtures formed stable amorphous solid dispersions (ASD). Furthermore, the rank order of the crystallization tendency of drug–polymer systems correlated well with those on miscibility and molecular interactions. Those rank orders also correlated well with the stability of prepared/reported SDs. Hence, the developed approach has significant potential to be a rational screening method for the development of amorphous SDs.
UR - http://www.scopus.com/inward/record.url?scp=85105155733&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105155733&partnerID=8YFLogxK
U2 - 10.1080/03639045.2021.1892747
DO - 10.1080/03639045.2021.1892747
M3 - Article
C2 - 33651659
AN - SCOPUS:85105155733
VL - 47
SP - 579
EP - 608
JO - Drug Development and Industrial Pharmacy
JF - Drug Development and Industrial Pharmacy
SN - 0363-9045
IS - 4
ER -